DrugBiological
Itolizumab clinical trials
Also written Bmab600 and EQ001.
- studies test it
- 10
- open now
- 2
- in phase 3
- 2
- first study started
- 2014
Keep track of what changes. Save the itolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
10 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 2
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Biocon Limited (5) · Biotech Pharmaceutical Co., Ltd. (4) · Equillium (1)
Studies
Open first, then newest update. How each study uses itolizumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Safety and Preliminary Clinical Activity of Itolizumab in DermatomyositisNot yet recruitingPhase 1Biotech Pharmaceutical Co., Ltd.NCT05986162Written as Itolizumab
- Safety and Preliminary Clinical Activity of Itolizumab in ARDSNot yet recruitingPhase 1Biotech Pharmaceutical Co., Ltd.NCT05978544Written as Itolizumab
- A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHDCompletedPhase 1/2Biocon LimitedNCT03763318Written as EQ001
- Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative NephritisCompletedPhase 1Biocon LimitedNCT04128579Written as Itolizumab [Bmab 600]
- A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled AsthmaCompletedPhase 1Biocon LimitedNCT04007198Written as EQ001
- A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19WithdrawnPhase 3Biocon LimitedNCT04605926Written as EQ001
- A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)TerminatedPhase 3EquilliumNCT05263999Written as Itolizumab
- Safety and Clinical Activity of Itolizumab in aGVHDStatus unknownPhase 1Biotech Pharmaceutical Co., Ltd.NCT05823675Written as Itolizumab
- Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese PsoriasisTerminatedPhase 1Biotech Pharmaceutical Co., Ltd.NCT02649270Written as T1h
- Efficacy and Safety of Itolizumab in COVID-19 ComplicationsCompletedPhase 2Biocon LimitedNCT04475588Written as Itolizumab IV infusion
Codes
What other systems call itolizumab · ClinicalTrials.gg INT000216
- MeSH (NLM) C000597346itolizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) XQQ2RHV14NITOLIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6094826ItolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95787ItolizumabOne source FDA
- DrugBank DB16207One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000597346 | itolizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | XQQ2RHV14N | ITOLIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6094826 | Itolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95787 | Itolizumab | One source FDA |
| DrugBank | DB16207 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.